Founded in October 2005 by Patrizia d´Alessio, MD PhD - AISA Therapeutics is dedicated to the development and commercialization of anti-inflammatory / anti-senescence drugs, based on a novel concept.
AISA Therapeutics aims at developing pharmacological products which modulate the inflammation pathways.
AISA Therapeutics targets organ-specific vascular-endothelium based pathologies, such as chronic inflammatory diseases, which may develop in gastro-intestinal, joint or cardiovascular clinical settings. AISA Therapeutics molecules have also been validated for their anti-stress effects. Hence, AISA Therapeutics is cooperating with licensing partners as new drugs for human and animal health will be developed in two main indications:
- in human health: inflammation resulting from stress; skin frailty in the elderly; dermatitis and colitis;
- in animal health: stress and inflammatory syndromes.
Moreover, AISA molecules are naturally occurring entities present in edible plants (food) and not toxic, thus allowing a nutraceutical approach for all indications mentioned.
AISA molecules are non-toxic, have an anti-inflammatory effect and display anti-senescence activity.